cisplatin,pembrolizumab,tremelimumab,durvalumab,nivolumab,ipilimumab
astrazeneca,bms,merck
['gu ', 'pembro', 'cisplatin', 'durva', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'blcsm', 'biomarker', 'check,mate,901', 'tremelimumab']
great discussion by dr. of the future
of #io in first line treatment in #blcsm
#gu23 
Oncólogo Clínico staff @IAF_Fleming. Miembro @SelnetH2020 @aaoncoclinica. Interesado en #GUcsm. #clinicaltrials. #Immunotherapy #PrecisionMedicine #oncoalert